Arcutis Biotherapeutics ARQT 深 沪

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

03-28 15:00

Arcutis Biotherapeutics To Present New Data From Its Clinical Development Program And Marketed ZORYVE Portfolio

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its

03-18 20:06

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

Arcutis Biotherapeutics will present new data on ZORYVE at the 2026 American Academy of Dermatology Annual Meeting. The presentations include late-breaking results from the INTEGUMENT-INFANT Phase 2 trial for infants with atopic dermatitis, as well as outcomes from the INTEGUMENT-OLE Phase 3 trial in children aged 2-5 years. Additional e-posters will highlight long-term results in seborrheic dermatitis and plaque psoriasis. ZORYVE (roflumilast), ...

03-18 12:00

Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline

Arcutis Biotherapeutics Inc ($ARQT) announced an update on their ongoing clinic...

03-10 00:30

Arcutis Promotes Mas Matsuda to EVP and Chief Legal Officer

Arcutis Promotes Mas Matsuda to EVP and Chief Legal Officer Arcutis Biotherapeutics Inc. promoted Mas Matsuda from senior vice president and general counsel to executive vice president, chief legal officer, and corporate secretary. Matsuda, who joined the company in January 2022, will continue to le

03-05 22:03

BRIEF-Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis

BRIEF-Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis March 3 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O : ARCUTIS BEGINS ENROLLING PHASE 1A/1B STUDY EVALUATING ARQ-234, A CD200R AGONIST, IN HEALTHY VOLUNTEE

03-03 21:03

Arcutis enrolls first participant in Phase 1a/1b ARQ-234 atopic dermatitis trial

Arcutis enrolls first participant in Phase 1a/1b ARQ-234 atopic dermatitis trial Arcutis Biotherapeutics Inc. announced enrollment of the first participant in ARQ-234-131, a Phase 1a/1b double-blind, randomized, placebo-controlled, first-in-human study evaluating the safety and tolerability of ARQ-2

03-03 21:03

美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元

今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元

03-03 20:22

美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价

今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元

03-02 14:08

美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价

今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元

02-27 11:07